Within five years, 18.8% of them have heart failure,2 driven substantially by the inflammation that follows reperfusion rather than by the blockage preceding it.
Please note: Nuvara Therapeutics operates in a stealth capacity.
Name
Corporate email
Nature of inquiryPlease selectStrategic partneringInvestment inquiriesGeneral inquiries
We read what comes in and answer where we can. Your details are kept to reply to you and for nothing else. Privacy statement.